Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss over 2 months.
First-Line Treatment Selection in TP53 Co-Mutated EGFR-Positive Metastatic Non-Small Cell Lung Cancer
Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.
Compare EGFR lung cancer first-line options—osimertinib, amivantamab/lazertinib, or chemo combo—balancing visits, survival, and risks.
Trial data guide EGFR lung cancer first-line choices: amivantamab+lazertinib may edge osimertinib+chemo, especially with TP53 mutations.
New trial data weigh EGFR lung cancer first-line combos, hinting amivantamab–lazertinib may edge osimertinib plus chemo, especially with TP53.
EGFR lung cancer trials show combo therapy better prevents brain metastases, improving intracranial response and PFS compared with osimertinib alone.